Lucile M.
- Country
- France
- Department
- Service d'Hépatologie
Research Overview
- Evaluation of Metformin on Hepatic Venous Pressure Gradient in Cirrhotic Patients with Portal Hypertension Under Carvedilol Therapy: A Randomized, Placebo-Controlled Trial
- Efficacy and Safety Evaluation of Zibotentan and Dapagliflozin in Patients with Liver Cirrhosis and Portal Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 1 of 31 partner sites.
Specializations
Hepatic Studies
The investigator specializes in treating liver cirrhosis and its complications, with particular emphasis on portal hypertension. Their research explores innovative therapeutic approaches for managing cirrhotic patients.
- Portal Hypertension Management
- Cirrhosis Complications
- Hepatic Vascular Pressure Monitoring
The investigator's work focuses on evaluating combination therapies and novel treatment strategies for patients with advanced liver disease.
Therapeutic Innovations
Their research investigates the clinical applications of various therapeutic agents, including zibotentan and dapagliflozin combinations, as well as metformin for portal hypertension treatment.
- Combination Drug Therapy
- Pressure Gradient Assessment
- Treatment Optimization
The investigator evaluates both established and emerging medications for improving outcomes in cirrhotic patients.
Clinical Management
The investigator's expertise extends to the comprehensive management of cirrhosis complications, with special attention to patients already receiving standard treatments such as carvedilol.
- Disease Progression Monitoring
- Treatment Response Assessment
- Long-term Patient Care
Their work encompasses both acute intervention strategies and long-term therapeutic management approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.